I research the businesses
I would want to own.

I grew up in Hangzhou, moved to South Devon at sixteen on a YFU exchange, returned to HFLS for A-levels (five A*s, TMUA 9/9), and won the Harvard International Economics Essay Competition with a multi-scenario game-theory model on US–China escalation. I now read filings the way I once read history.

Two motivations sit underneath the work. The first is to understand how value gets created and unlocked — which is why M&A, valuation, and pair-trade frameworks attract me more than macro or rate-trading. The second is to build, not only analyse — why I founded a £17k tutoring venture across seven countries at seventeen, ran a 150-person alumni football tournament, and co-founded the IBD branch of LSE Advisory Group from inception in April.

My sector edge is healthcare. Across my pitch library, multiple deep biopharm shorts (Upstream Bio, Innovent, Mirum, Jazz) and large-cap longs (Novo Nordisk, BeOne, Denali) are built bottom-up — rNPV with PoS-by-stage, indication-level forecasts, biosimilar erosion, patent cliffs, and named clinical-trial catalysts. My UPB short, the basis of the Silver Medal at MBP × Citadel, realised its 81.8% target downside post-submission.